Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,138 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integration of genetics and MRD to define low risk patients with B-cell precursor acute lymphoblastic leukaemia with intermediate MRD levels at the end of induction.
Moorman AV, Enshaei A, Murdy D, Joy M, Boer JM, den Boer ML, Pieters R, de Haas V, Horstmann MA, Escherich G, Johansson B, Marquart HV, Schmiegelow K, Hancock J, Moppett J, Heyman M. Moorman AV, et al. Among authors: hancock j. Leukemia. 2024 Sep;38(9):2023-2026. doi: 10.1038/s41375-024-02329-0. Epub 2024 Jul 5. Leukemia. 2024. PMID: 38965371 Free PMC article. No abstract available.
A validated novel continuous prognostic index to deliver stratified medicine in pediatric acute lymphoblastic leukemia.
Enshaei A, O'Connor D, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, den Boer ML, Boer JM, de Groot-Kruseman HA, Marquart HV, Noren-Nystrom U, Schmiegelow K, Schwab C, Horstmann MA, Escherich G, Heyman M, Pieters R, Vora A, Moppett J, Moorman AV. Enshaei A, et al. Among authors: hancock j. Blood. 2020 Apr 23;135(17):1438-1446. doi: 10.1182/blood.2019003191. Blood. 2020. PMID: 32315382 Free article.
Time to Cure for Childhood and Young Adult Acute Lymphoblastic Leukemia Is Independent of Early Risk Factors: Long-Term Follow-Up of the UKALL2003 Trial.
Moorman AV, Antony G, Wade R, Butler ER, Enshaei A, Harrison CJ, Moppett J, Hough R, Rowntree C, Hancock J, Goulden N, Samarasinghe S, Vora A. Moorman AV, et al. Among authors: hancock j. J Clin Oncol. 2022 Dec 20;40(36):4228-4239. doi: 10.1200/JCO.22.00245. Epub 2022 Jun 17. J Clin Oncol. 2022. PMID: 35714315 Clinical Trial.
Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial.
Parker C, Krishnan S, Hamadeh L, Irving JAE, Kuiper RP, Révész T, Hoogerbrugge P, Hancock J, Sutton R, Moorman AV, Saha V. Parker C, et al. Among authors: hancock j. Lancet Haematol. 2019 Apr;6(4):e204-e216. doi: 10.1016/S2352-3026(19)30003-1. Epub 2019 Feb 27. Lancet Haematol. 2019. PMID: 30826273 Free PMC article. Clinical Trial.
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
Brüggemann M, Kotrová M, Knecht H, Bartram J, Boudjogrha M, Bystry V, Fazio G, Froňková E, Giraud M, Grioni A, Hancock J, Herrmann D, Jiménez C, Krejci A, Moppett J, Reigl T, Salson M, Scheijen B, Schwarz M, Songia S, Svaton M, van Dongen JJM, Villarese P, Wakeman S, Wright G, Cazzaniga G, Davi F, García-Sanz R, Gonzalez D, Groenen PJTA, Hummel M, Macintyre EA, Stamatopoulos K, Pott C, Trka J, Darzentas N, Langerak AW; EuroClonality-NGS working group. Brüggemann M, et al. Among authors: hancock j. Leukemia. 2019 Sep;33(9):2241-2253. doi: 10.1038/s41375-019-0496-7. Epub 2019 Jun 26. Leukemia. 2019. PMID: 31243313 Free PMC article.
Genotype-Specific Minimal Residual Disease Interpretation Improves Stratification in Pediatric Acute Lymphoblastic Leukemia.
O'Connor D, Enshaei A, Bartram J, Hancock J, Harrison CJ, Hough R, Samarasinghe S, Schwab C, Vora A, Wade R, Moppett J, Moorman AV, Goulden N. O'Connor D, et al. Among authors: hancock j. J Clin Oncol. 2018 Jan 1;36(1):34-43. doi: 10.1200/JCO.2017.74.0449. Epub 2017 Nov 13. J Clin Oncol. 2018. PMID: 29131699 Free PMC article. Clinical Trial.
Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial.
Vora A, Goulden N, Mitchell C, Hancock J, Hough R, Rowntree C, Moorman AV, Wade R. Vora A, et al. Among authors: hancock j. Lancet Oncol. 2014 Jul;15(8):809-18. doi: 10.1016/S1470-2045(14)70243-8. Epub 2014 Jun 9. Lancet Oncol. 2014. PMID: 24924991 Clinical Trial.
Excellent outcome of minimal residual disease-defined low-risk patients is sustained with more than 10 years follow-up: results of UK paediatric acute lymphoblastic leukaemia trials 1997-2003.
Bartram J, Wade R, Vora A, Hancock J, Mitchell C, Kinsey S, Steward C, Moppett J, Goulden N. Bartram J, et al. Among authors: hancock j. Arch Dis Child. 2016 May;101(5):449-54. doi: 10.1136/archdischild-2015-309617. Epub 2016 Feb 10. Arch Dis Child. 2016. PMID: 26865705 Clinical Trial.
1,138 results